Ferrannini (MB102013) 2010

NCT00528372

1 Treatments

Studied treatment  a morning dose of 5 or 10 mg/day dapagliflozin

Control treatment  placebo

Concomittant treatments  -

2 Patients

Patients  treatment-naive patients with type 2 diabetes

Inclusion criteria  -

Exclusion criteria  -

3 Methods

Blinding  double-blind

Design  -

Centers  -

Geographical area  -

Sizes  -9/-9

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>stroke</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>MI</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all cause deaths</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV events</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV deaths</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>
5 References
